[Form 4] Nvidia Corp Insider Trading Activity

Rhea-AI Filing Summary

Athira Pharma, Inc. (ATHA) has filed a Form 144 indicating the planned sale of 8,526 common shares through broker Morgan Stanley Smith Barney LLC. The proposed transaction represents approximately 0.022 % of the company’s 39.0 million shares outstanding and carries an aggregate market value of $2,502 based on the price at the time of filing. The shares originate from a restricted-stock lapse dated 30 June 2025 and are scheduled to be sold on or after 1 July 2025 on the NASDAQ exchange. No previous insider sales were reported during the last three months, and the filer asserts the standard representation of having no undisclosed adverse information about the company.

The notice is procedural, providing investors with transparency into a forthcoming, modest-size insider disposition. Given the small fraction of total shares and the absence of other material operational or financial disclosures, the filing is unlikely to have a meaningful impact on ATHA’s share price or fundamentals.

Insights

Financial Analyst

TL;DR: Minor insider sale of 8.5k ATHA shares (<0.03 % of float); negligible market impact expected.

The Form 144 discloses that an insider intends to sell 8,526 common shares, valued at roughly $2.5 k, via Morgan Stanley. With 39 million shares outstanding, the planned sale is immaterial from a liquidity or signaling standpoint. No pattern of recent selling and no adverse business information are indicated. Investors typically monitor Form 144s for sentiment clues, but this transaction’s size suggests a routine liquidity event following the vesting of restricted stock rather than a bearish outlook. I therefore view the filing as neutral for valuation and trading purposes.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HUANG JEN HSUN

(Last) (First) (Middle)

C/O NVIDIA CORPORATION

2788 SAN TOMAS EXPRESSWAY

(Street)

SANTA CLARA CA 95051

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NVIDIA CORP [ NVDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
06/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/27/2025		S(1)		17,774	D	$156.0159(2)	75,455,451	D
Common Stock	06/27/2025		S(1)		27,574	D	$156.8974(3)	75,427,877	D
Common Stock	06/27/2025		S(1)		26,947	D	$157.6498(4)	75,400,930	D
Common Stock	06/27/2025		S(1)		2,705	D	$158.4551(5)	75,398,225	D
Common Stock	06/30/2025		S(1)		19,624	D	$156.8135(6)	75,378,601	D
Common Stock	06/30/2025		S(1)		49,070	D	$157.7268(7)	75,329,531	D
Common Stock	06/30/2025		S(1)		6,306	D	$158.2701(8)	75,323,225	D
Common Stock	07/01/2025		S(1)		4,497	D	$152.2292(9)	75,318,728	D
Common Stock	07/01/2025		S(1)		14,104	D	$153.0139(10)	75,304,624	D
Common Stock	07/01/2025		S(1)		21,050	D	$153.7314(11)	75,283,574	D
Common Stock	07/01/2025		S(1)		18,612	D	$154.6027(12)	75,264,962	D
Common Stock	07/01/2025		S(1)		12,561	D	$156.0585(13)	75,252,401	D
Common Stock	07/01/2025		S(1)		4,176	D	$156.6425(14)	75,248,225	D
Common Stock								582,503,470	I	By Trust(15)
Common Stock								49,489,560	I	By Partnership(16)
Common Stock								22,280,000	I	By Irrevocable Trust(17)
Common Stock								50,078,000	I	By Irrevocable Remainder Trust(18)
Common Stock								29,512,185	I	By Grantor Retained Annuity Trust 1(19)
Common Stock								29,512,185	I	By Grantor Retained Annuity Trust 2(20)
Common Stock								10,000,000	I	By Limited Liability Company 1(21)
Common Stock								10,000,000	I	By Limited Liability Company 2(22)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 20, 2025.

2. Represents weighted average sales price. The shares were sold at prices ranging from $155.350 to $156.340. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

3. Represents weighted average sales price. The shares were sold at prices ranging from $156.345 to $157.330. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

4. Represents weighted average sales price. The shares were sold at prices ranging from $157.340 to $158.330. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

5. Represents weighted average sales price. The shares were sold at prices ranging from $158.335 to $158.675. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

6. Represents weighted average sales price. The shares were sold at prices ranging from $156.135 to $157.120. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

7. Represents weighted average sales price. The shares were sold at prices ranging from $157.130 to $158.120. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

8. Represents weighted average sales price. The shares were sold at prices ranging from $158.130 to $158.600. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

9. Represents weighted average sales price. The shares were sold at prices ranging from $151.540 to $152.530. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

10. Represents weighted average sales price. The shares were sold at prices ranging from $152.535 to $153.335. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

11. Represents weighted average sales price. The shares were sold at prices ranging from $153.345 to $154.330. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

12. Represents weighted average sales price. The shares were sold at prices ranging from $154.340 to $155.295. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

13. Represents weighted average sales price. The shares were sold at prices ranging from $155.360 to $156.350. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

14. Represents weighted average sales price. The shares were sold at prices ranging from $156.360 to $157.100. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

15. The shares are held by Jen-Hsun Huang and Lori Huang, as co-trustees of the Jen-Hsun & Lori Huang Living Trust, u/a/d May 1, 1995 (the "Trust").

16. The shares are held by J. and L. Huang Investments, L.P., of which the Trust is the general partner.

17. The shares are held by The Huang 2012 Irrevocable Trust, of which the Reporting Person is a trustee.

18. The shares are held by The Huang Irrevocable Remainder Trust u/a/d February 19, 2016, of which the Reporting Person is a trustee.

19. The shares are held by The Lori Lynn Huang 2016 Annuity Trust II Agreement.

20. The shares are held by The Jen-Hsun Huang 2016 Annuity Trust II Agreement.

21. The shares are held by TARG S LLC, of which the Trust is the sole member.

22. The shares are held by TARG M LLC, of which the Trust is the sole member.

Remarks:

	/s/ Rebecca Peters, Attorney-in-Fact for Jen-Hsun Huang	07/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Athira Pharma (ATHA) shares are being sold under this Form 144?

The notice covers 8,526 common shares of Athira Pharma.

What percentage of ATHA’s outstanding shares does the 8,526-share sale represent?

It equals roughly 0.022 % of the 39,042,445 shares outstanding.

When is the approximate sale date for the ATHA shares?

The filer listed 01 July 2025 as the anticipated sale date.

What was the source of the shares being sold?

They were acquired via a restricted stock lapse on 30 June 2025 as part of equity compensation.

Which broker will execute the ATHA share sale?

The broker of record is Morgan Stanley Smith Barney LLC.